The symptoms of aGVHD typically appear within the first 100 days after transplantation. Common signs include:

• Skin: Rash, redness, and peeling, often starting on the palms and soles and spreading to other areas.
• Liver: Jaundice (yellowing of the skin and eyes), elevated liver enzymes, and liver enlargement.
• Gastrointestinal Tract: Nausea, vomiting, diarrhea, and abdominal pain.

The severity of aGVHD can vary, ranging from mild to life-threatening, depending on the extent of organ involvement.

Diagnosing aGVHD involves a combination of clinical evaluation and laboratory tests. A thorough physical examination is conducted to assess the extent of skin, liver, and gastrointestinal involvement. Blood tests are performed to check liver function and other organ systems. In some cases, a biopsy of the affected organ (skin, liver, or gut) may be necessary to confirm the diagnosis and rule out other conditions.

The primary treatment for aGVHD is immunosuppression, which involves using medications to dampen the immune response. Corticosteroids, such as prednisone, are commonly used as the first line of treatment. If the disease does not respond to steroids, other immunosuppressive agents, like cyclosporine or tacrolimus, may be used. Supportive care, including nutritional support and management of symptoms, is also crucial in the treatment plan.

The prognosis for aGVHD varies depending on the severity of the disease and the response to treatment. Mild cases often respond well to treatment and have a good prognosis. However, severe cases can lead to significant complications and may be life-threatening. Early diagnosis and prompt treatment are essential for improving outcomes.

aGVHD occurs when the donor's immune cells recognize the recipient's body as foreign and attack it. This immune response is more likely when there is a mismatch between the donor and recipient's human leukocyte antigens (HLAs), which are proteins on the surface of cells that help the immune system distinguish between self and non-self.

aGVHD is a common complication of allogeneic stem cell transplantation, where the donor and recipient are different individuals. The incidence of aGVHD varies, affecting approximately 30-50% of transplant recipients. The risk is higher in cases with greater HLA mismatches and in older recipients.

The pathophysiology of aGVHD involves three main phases:

1. Initiation: The conditioning regimen (chemotherapy and/or radiation) used before transplantation damages the recipient's tissues, releasing inflammatory signals.
2. Activation: Donor T-cells (a type of immune cell) become activated by these signals and recognize the recipient's tissues as foreign.
3. Effector Phase: The activated T-cells attack the recipient's tissues, leading to the symptoms of aGVHD.

Preventing aGVHD involves strategies to reduce the risk of donor immune cells attacking the recipient. This includes careful matching of donor and recipient HLAs and using immunosuppressive medications before and after transplantation to prevent immune activation. Some centers also use T-cell depletion techniques to reduce the number of donor T-cells in the graft.

Acute Graft-Versus-Host Disease is a serious complication of stem cell transplantation, where the donor's immune cells attack the recipient's body. It primarily affects the skin, liver, and gastrointestinal tract. Early diagnosis and treatment with immunosuppressive medications are crucial for managing the disease and improving outcomes. Preventive strategies focus on careful donor-recipient matching and immunosuppression.

If you or a loved one is undergoing a stem cell transplant, it's important to be aware of the signs and symptoms of aGVHD, such as skin rashes, jaundice, and gastrointestinal issues. Early recognition and treatment are key to managing this condition effectively. Discuss any concerns with your healthcare team, who can provide guidance and support throughout the transplant process.